ZVRA

8.7603.42%
NF

Neil F. McFarlane

President, CEO & Director

Mr. Neil F. McFarlane serves as the Member of Board of Managers of HCRx Holdings at Healthcare Royalty Management, LLC. He is in this position since January 2024. He serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He served as Independent Director at Collegium Pharmaceutical, Inc. since April 06, 2022 until 2024. Mr. McFarlane served as Chief Executive Officer and Director of Adamas Pharmaceuticals, Inc. since September 16, 2019 until November 24, 2021. Mr. McFarlane served as Chief Operating Officer of Retrophin, Inc. since August 15, 2016 until May 31, 2019. Mr. McFarlane served as Vice President of Immunology Business Unit at UCB, Inc. and was responsible for the Global Bone Business in collaboration with Amgen. Mr. McFarlane served as the Vice President, Bone business unit for UCB, Inc. a biopharmaceutical company, since 2013, in which role he was responsible for leading the global collaboration with Amgen and from 2011 to 2013. Mr. McFarlane held positions of increasing responsibility with Genzyme Corporation, a biotechnology company and Sangstat Medical Corporation prior to its acquisition by Genzyme. He has significant experience, having held positions of increasing responsibility at leading biopharmaceutical companies, including UCB and Sanofi Genzyme. Mr. McFarlane also served as General Manager of Immunology during his tenure at UCB. This was preceded by roles as Vice President of International Transplant and as Vice President of Transplant while at Genzyme. Mr. McFarlane served as an officer and enlisted soldier in the United States Army Reserves. Mr. McFarlane received his Bachelor of Science and Master of Science in Nursing from the University of Florida.

Positions